#394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplements
Release Date: 06/01/2026
The Peter Attia Drive
In this episode, Peter returns to the topic of peptides, offering a clear and accessible guide to a field surrounded by both genuine scientific promise and widespread misinformation. Peptides are increasingly marketed for everything from injury recovery and muscle growth to longevity and improved appearance, often with claims that extend far beyond the available evidence. Rather than promoting or dismissing peptides as a category, Peter presents a practical framework for evaluating any peptide: what it is, how it is supposed to work, and where the science is strong, weak, or simply absent....
info_outlineThe Peter Attia Drive
Jim Otvos is a biophysical chemist who pioneered the use of nuclear magnetic resonance (NMR) spectroscopy to measure lipoprotein particles and developed the first FDA-cleared method for directly quantifying LDL particle number (LDL-P), a technology that has since expanded to provide broader insights into metabolic health, inflammation, insulin resistance, and mortality risk. In this episode, Jim recounts the unlikely story of transforming a flawed cancer test into a new way of measuring lipoproteins, explains what standard cholesterol tests can miss and why LDL-P and apoB can inform...
info_outlineThe Peter Attia Drive
In this episode of The Drive, Peter explores how seemingly obscure basic science discoveries have laid the foundation for some of the most important medical breakthroughs of the past half century. Rather than focusing on the clinical applications of modern therapies, he traces the fascinating stories behind the scientists, experiments, and unexpected discoveries that ultimately led to transformative drug classes, revealing how groundbreaking advances often emerge from research with no obvious clinical goal. Through these historical case studies, Peter provides a new perspective on the...
info_outlineThe Peter Attia Drive
In this “Ask Me Anything” (AMA) episode, Peter explores the evidence behind environmental pollution and its impact on long-term health, separating well-supported risks from less substantiated claims while providing a practical framework for deciding which exposures deserve attention. He explains what environmental pollution encompasses, where it fits within the broader hierarchy of longevity interventions, and why studying its health effects is uniquely challenging. Peter examines the evidence linking air pollution to disease and shares actionable strategies for improving indoor and...
info_outlineThe Peter Attia Drive
Gayatri Devi is a nationally recognized neurologist specializing in memory disorders, including Alzheimer’s disease and related dementias. In this episode, Gayatri explains how to think about dementia as a spectrum—including Alzheimer’s disease, vascular dementia, Lewy body dementia, and mixed presentations—while exploring the evolving biology of amyloid, tau, and neuroinflammation and why brain pathology does not always correlate with symptoms. She discusses her approach to detecting subtle cognitive decline in high-functioning individuals, the role of biomarkers and APOE4 testing...
info_outlineThe Peter Attia Drive
In this “Ask Me Anything” (AMA) episode, Peter dives deep into the topic of muscle mass and strength, examining their essential roles in both lifespan and healthspan. Drawing from over 30 hours of prior discussions with experts including Layne Norton, Andy Galpin, and Mike Israetel, this episode distills the most important insights into one comprehensive and up-to-date conversation. Peter explores why muscle matters for longevity, metabolic health, and injury prevention, and clarifies the differences between muscle mass and strength, including which is more vital for aging well. He...
info_outlineThe Peter Attia Drive
In this “Ask Me Anything” (AMA) episode, Peter explores the effects of GLP-1 receptor agonists—including drugs such as Ozempic, Wegovy, and Zepbound—with a particular focus on their impact on muscle. He examines how much lean mass people actually lose during treatment and how those changes compare to weight loss achieved through other methods, while explaining why measurements of lean mass on DEXA scans can sometimes be misleading. Peter discusses the effects of these medications on bone mass, fracture risk, strength, and physical function, highlighting why functional outcomes may...
info_outlineThe Peter Attia Drive
Renato Tomioka is a leading expert in reproductive medicine and gynecologic surgery whose unique skills allow him to diagnose and treat some of the most impactful yet frequently overlooked conditions affecting women’s health. In this episode, Renato explores endometriosis and adenomyosis, explaining what these conditions are, why they often go undiagnosed for years despite affecting millions of women worldwide, and how advances in MRI and specialized ultrasound are transforming diagnosis beyond traditional surgical laparoscopy. He discusses the decision-making process behind hormonal...
info_outlineThe Peter Attia Drive
In this episode, Peter explores the critical topic of breast cancer screening, examining why thousands of women continue to die from breast cancer each year despite the availability of effective screening tools. He explains the strengths and limitations of current screening strategies, reviews the recommendations from major medical organizations, and discusses why screening guidance can often seem confusing or contradictory. Peter outlines a practical framework for understanding breast cancer risk and personalizing screening decisions, including when to begin screening, how frequently to...
info_outlineThe Peter Attia Drive
Tom Dayspring is a world-renowned lipidologist and one of the most thoughtful teachers in the field of lipid metabolism. In this episode, Tom returns to The Drive for a deep dive into the relationship between lipids and brain health, beginning with the fundamentals of cholesterol transport before exploring why the brain’s cholesterol system operates almost entirely independently from the rest of the body. Tom examines the roles of apoB, apoA-I, and especially apoE in cholesterol homeostasis, discusses how APOE genotype influences Alzheimer’s disease risk, and unpacks the complex links...
info_outlineView the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter’s Weekly Newsletter
In this episode, Peter dives into the pharmacology of sleep, exploring where sleep medications fit within the broader framework of achieving healthy, restorative sleep. He explains why sleep is a biological imperative, why behavioral and environmental interventions must remain the foundation of good sleep, and how medications can serve as useful tools when carefully matched to a person’s specific sleep problem. Peter examines the major classes of prescription sleep medications, including how they work, their effects on sleep architecture, their duration of action, side effects, and risks of tolerance and dependence. He also discusses the dangers of using sleep drugs without a clear understanding of the underlying problem being treated, the role of medications as short-term bridges during periods of acute stress, pain, or anxiety, and the promise that newer drugs like DORAs may hold for Alzheimer’s prevention in high-risk individuals. Finally, Peter reviews the evidence for select off-label medications and supplements commonly used for sleep.
We discuss:
- The biological foundations of sleep, the major drivers of sleep dysfunction, and the role sleep medications can play when appropriately matched to specific sleep problems [1:00];
- Sleep hygiene, circadian alignment, and the medical causes of insomnia: building the foundation for effective sleep treatment [7:15];
- Understanding insomnia: hyperarousal, CBT-I, paradoxical insomnia, and why different sleep problems require different treatments [12:45];
- The difference between sedation and physiologic sleep: sleep architecture, restorative sleep stages, and matching medications to specific sleep problems [17:00];
- Benzodiazepines for insomnia: mechanisms, effects on sleep architecture, and the risks of long-term use [18:45];
- Z-drugs for insomnia: how Ambien, Sonata, and Lunesta work, and the ongoing risks of sleep medications targeting GABA systems [23:00];
- Dual orexin receptor antagonists (DORAs) and the future of sleep medicine: orexin signaling, sleep architecture, and the emerging connection between sleep and Alzheimer’s disease [27:15];
- Melatonin for circadian timing: how timing signals differ from sedatives in the treatment of sleep disorders [36:30];
- Trazodone for insomnia: preserving deep sleep while minimizing the risks of traditional sedative-hypnotics [42:00];
- First-generation antihistamines for sleep: short-term sedation, anticholinergic risks, and concerns about long-term cognitive health [44:00];
- Sleep supplements and the evidence behind them: glycine, magnesium, ashwagandha, phosphatidylserine, and more [45:45];
- Takeaways: supplement quality, individualized sleep treatment, and the importance of matching interventions to the biology of insomnia [52:00]; and
- More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube